Home Cart Sign in  
Chemical Structure| 209986-17-4 Chemical Structure| 209986-17-4

Structure of Compound E
CAS No.: 209986-17-4

Chemical Structure| 209986-17-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Compound E is an inhibitor of γ-Secretase.

Synonyms: γ-Secretase-IN-1; γ-Secretase Inhibitor XXI; GSI-XXI

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Compound E

CAS No. :209986-17-4
Formula : C27H24F2N4O3
M.W : 490.50
SMILES Code : O=C(N[C@@H](C)C(N[C@@H]1C(N(C)C2=CC=CC=C2C(C3=CC=CC=C3)=N1)=O)=O)CC4=CC(F)=CC(F)=C4
Synonyms :
γ-Secretase-IN-1; γ-Secretase Inhibitor XXI; GSI-XXI
MDL No. :MFCD04974531
InChI Key :JNGZXGGOCLZBFB-IVCQMTBJSA-N
Pubchem ID :11306390

Safety of Compound E

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MT-1 cells 5μM 24 h Compound E induced caspase-9 and caspase-3 activities. Leukemia. 2015 Mar;29(3):556-66
MT-1 cells 10μM 48 h Compound E induced apoptosis in MT-1 cells. Leukemia. 2015 Mar;29(3):556-66
IMR-32 neuroblastoma cells 10 μM 5 days To evaluate the effects of GSIs alone or in combination with 13-cis retinoic acid (RA) on neuroblastoma cell growth, differentiation, and migration. Results showed that GSIs alone induced complete cell growth arrest, promoted neuronal differentiation, and significantly reduced cell motility. The combination with 13-cis RA enhanced these effects. Neuro Oncol. 2010 Dec;12(12):1231-43
SH-SY5Y neuroblastoma cells 10 μM 5 days To evaluate the effects of GSIs alone or in combination with 13-cis retinoic acid (RA) on neuroblastoma cell growth, differentiation, and migration. Results showed that GSIs alone induced complete cell growth arrest, promoted neuronal differentiation, and significantly reduced cell motility. The combination with 13-cis RA enhanced these effects. Neuro Oncol. 2010 Dec;12(12):1231-43
MT-1 cells 0, 0.1, 0.5, 1.25, 2.5, 5 or 10μM 48 h Compound E suppressed MT-1 cell proliferation in a dose-dependent manner. Leukemia. 2015 Mar;29(3):556-66
HK-2 cells 100 nM 72 h To evaluate the effects of Compound E on TGF-β1 and fibronectin secretion in HK-2 cells. Results showed that Compound E alone significantly increased TGF-β1 and fibronectin secretion, similar to the effects of high albumin concentrations. Br J Pharmacol. 2013 Jul;169(6):1239-51
Bovine polymorphonuclear neutrophils (PMN) 20 nM 30 min Inhibition of Notch signaling to assess its effect on C. parvum-induced NETosis. Results showed that Compound E significantly reduced NET formation. Biology (Basel). 2022 Mar 14;11(3):442
bovine monocytes 20 nM 30 min Inhibition of Notch signaling pathway, reducing C. parvum-induced METosis Biology (Basel). 2023 Jul 5;12(7):961

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOG mice MT-1 adult T-cell leukemia model Subcutaneous osmotic pump 10μmol/Kg Continuous administration for 28 days Compound E alone or in combination with Bortezomib and Romidepsin significantly inhibited tumor growth and prolonged the survival of leukemia-bearing mice. Leukemia. 2015 Mar;29(3):556-66

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.19mL

2.04mL

1.02mL

20.39mL

4.08mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories